Hengrui Medicine: The indication of Haiqu Boethanolamine Tablet has been approved by the National Medical Products Administration.

Hengrui Medicine announced that the company's independently developed innovative drug Hepmiroptap Ethanolamine tablets of Class 1 have obtained approval for new indications from the National Medical Products Administration. This drug, when used in combination with immunosuppressive therapy, is suitable for first-line treatment of severe aplastic anemia in patients aged 15 and above. The drug has already been approved for two indications in 2021. As of now, approximately 633 million yuan has been invested in the research and development of the related projects. The production and sales of the drug after approval may be affected by uncertain factors, and investors are advised to pay attention to the risks.